Results 51 to 60 of about 347 (81)

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registry

open access: yesHematology
Background: Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) for treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in patients who fail or are intolerant to a second ...
Timothy Devos   +21 more
doaj   +1 more source

How Does the Method Used to Measure the VE/VCO2 Slope Affect Its Value? A Cross-Sectional and Retrospective Cohort Study. [PDF]

open access: yesHealthcare (Basel), 2023
Chaumont M   +4 more
europepmc   +1 more source

Determination of phage susceptibility as a clinical diagnostic tool: A routine perspective. [PDF]

open access: yesFront Cell Infect Microbiol, 2022
Daubie V   +10 more
europepmc   +1 more source

Wearable Sensors Applied in Movement Analysis. [PDF]

open access: yesSensors (Basel), 2022
Buisseret F, Dierick F, Van der Perre L.
europepmc   +1 more source

P699: REAL-LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5-YEAR-DATA FROM A BELGIAN REGISTRY

open access: yesHemaSphere, 2022
T. Devos   +21 more
doaj   +1 more source

Regular monitoring of SARS-CoV-2 carriage and antibody levels against the virus helped maintain social interactions for Alzheimer's disease residents in a Belgian nursing home during the pandemic. [PDF]

open access: yesJ Alzheimers Dis Rep
Tytgat A   +22 more
europepmc   +1 more source

Association between sarcopenia, its components, and osteoporosis in the FRISBEE cohort. [PDF]

open access: yesBMC Musculoskelet Disord
Tchang SL   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy